Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Insulet faces significant business and financial risks from the potential emergence of another global pandemic or new variants of COVID-19. Such events could disrupt clinical trials and delay FDA product approvals, as seen with Omnipod 5 during the COVID-19 pandemic. A shift to remote work has heightened cybersecurity threats, posing risks to IT systems and data integrity. Furthermore, pandemics could severely impact Insulet’s supply chain, affecting manufacturing, distribution, and third-party services critical to product sterilization and delivery.
The average PODD stock price target is $321.50, implying 13.68% upside potential.
To learn more about Insulet’s risk factors, click here.
